Karuna Therapeutics surges on positive results from schizophrenia drug trial

Karuna Therapeutics

08/08/2022 12:23

** Shares of Karuna Therapeutics Inc  KRTX.O  rise ~38 to
$194 in premarket trading
    ** Says its experimental drug, KarXT, met the main goal in a
late-stage trial for schizophrenia  urn:newsml:reuters.com:*:nBw8YhpY8a
    ** Drug also met key secondary endpoints in the trial,
showing statistically significant reduction in symptoms like
delusions
    ** Plans to submit application to FDA for approval of drug
in mid-2023
    ** Up to Friday' close, stock up ~7% YTD



 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))